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Abstract
Tumor angiogenesis is an important therapeutic target in colorectal cancer (CRC). We 
aimed to identify novel genes associated with angiogenesis in CRC. Using RNA se-
quencing analysis in normal and tumor endothelial cells (TECs) isolated from primary 
CRC tissues, we detected frequent upregulation of adipocyte enhancer-binding pro-
tein 1 (AEBP1) in TECs. Immunohistochemical analysis revealed that AEBP1 is upreg-
ulated in TECs and stromal cells in CRC tissues. Quantitative RT-PCR analysis showed 
that there is little or no AEBP1 expression in CRC cell lines, but that AEBP1 is well ex-
pressed in vascular endothelial cells. Levels of AEBP1 expression in Human umbilical 
vein endothelial cells (HUVECs) were upregulated by tumor conditioned medium de-
rived from CRC cells or by direct coculture with CRC cells. Knockdown of AEBP1 sup-
pressed proliferation, migration, and in vitro tube formation by HUVECs. In xenograft 
experiments, AEBP1 knockdown suppressed tumorigenesis and microvessel forma-
tion. Depletion of AEBP1 in HUVECs downregulated a series of genes associated 
with angiogenesis or endothelial function, including aquaporin 1 (AQP1) and periostin 
(POSTN), suggesting that AEBP1 might promote angiogenesis through regulation of 
those genes. These results suggest that upregulation of AEBP1 contributes to tumor 
angiogenesis in CRC, which makes AEBP1 a potentially useful therapeutic target.
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1  | INTRODUC TION
Colorectal cancer (CRC) is the third most common cancer worldwide 
and accounts for approximately 10% of all newly diagnosed malignant 
diseases.1 Early stage CRCs are usually curable with endoscopic resec-
tion or surgery, whereas more advanced cases have poorer prognoses. 
A number of therapeutic agents, including chemotherapeutic drugs and 
mAbs, have been developed for the treatment of advanced CRCs, but the 
prognoses of patients with metastatic disease are still unsatisfactory.2,3
Active angiogenesis is a hallmark of cancer and is deeply involved 
in the progression and metastasis of CRC. For that reason, antian-
giogenic therapy is an important strategy used in the treatment of 
advanced disease.4 For example, bevacizumab, a mAb that binds to 
vascular endothelial growth factor (VEGF), is a standard component 
of the treatment for patients with metastatic CRC.5 However, current 
antiangiogenic therapies have yielded only moderate benefit in CRC.
Although they have not yet been fully characterized, it seems clear 
that tumor endothelial cells (TECs) play an essential role in tumor an-
giogenesis.6 Notably, the molecular features of TECs distinctly differ 
from those of normal endothelial cells (NECs). This makes a funda-
mental understanding of the differences between TECs and NECs in-
dispensable for development of specific and effective antiangiogenic 
therapies. Several studies have analyzed the gene expression patterns 
in TECs and their normal counterparts. For instance, using serial analy-
sis of gene expression with endothelial cells isolated from CRC tissues, 
St. Croix et al7 identified a series of tumor endothelial markers (TEMs). 
A subsequent study showed that one of those markers, TEM8 (also 
known as anthrax toxin receptor 1, ANTXR1), is a potential therapeu-
tic target in cancer.8 Another study used subtractive hybridization to 
compare gene expression profiles in endothelial cells isolated from CRC 
and normal tissues, and identified 17 genes specifically overexpressed 
in TECs.9 More recently, Naschberger et al10 isolated TECs from CRCs 
with different clinical outcomes. They undertook microarray analyses 
to screen for differentially expressed genes between TECs from CRCs 
with better or worse prognoses and found that SPARC-like protein 1 
(SPARCL1) regulates vessel homeostasis and contributes to a favorable 
prognosis of CRC. These studies proved that transcriptome analysis in 
endothelial cells isolated from clinical specimens is a potentially useful 
strategy for unraveling the mechanism of tumor angiogenesis.
In the present study, we aimed to identify novel TEC markers 
and potential therapeutic targets in CRC. To that end, we isolated 
TECs and corresponding NECs from surgically resected CRC tissues, 
and carried out RNA sequencing (RNA-seq) analysis. Our findings 
revealed that upregulation of adipocyte enhancer-binding protein 1 
(AEBP1) might promote tumor angiogenesis in CRCs.
2  | MATERIAL S AND METHODS
2.1 | Tissue samples and cell lines
Primary CRC tissues and adjacent normal colonic tissues were 
collected from Japanese patients (n = 14) who underwent 
surgical resection at Sapporo Medical University Hospital. 
Informed consent was obtained from all patients before col-
lection of the specimens. Approval of this study was ob-
tained from the Intuitional Review Board of Sapporo Medical 
University. Human umbilical vein endothelial cells (HUVECs) 
were purchased from Lonza and cultured in Endothelial Cell 
Basal Medium-2 (EBM-2) supplemented with an Endothelial 
Cell Growth Medium-2 (EGM-2) SingleQuots kit (Lonza) at 
37°C under 5% CO2. Where indicated, HUVECs were treated 
for 24 h with 10 ng/mL transforming growth factor-β (TGF-
β; PeproTech). Human dermal microvascular endothelial cells 
(HMVECs) were purchased from Lonza and cultured in EBM-2 
supplemented with an EGM-2 MV SingleQuots kit (Lonza) at 
37°C under 5% CO2. The CRC cell lines were obtained and cul-
tured as described previously.11
2.2 | Isolation of endothelial cells
Endothelial cells were isolated from CRC and normal colonic tis-
sue as described previously.7,9 In brief, we isolated endothelial 
cells from surgically resected tissues using Ab-coated magnetic 
beads. Tissues were minced with surgical blades and digested 
with collagenase type 1 (Worthington Biochemical) and DNase 
I (Worthington Biochemical) for 2 h at 37°C. The solution de-
rived from the tissue was filtered through mesh and added to 
ACK buffer (Thermo Fisher Scientific) to remove red blood cells. 
The resultant cell suspensions were then subjected to selection 
of epithelial cell populations using Dynabeads Epithelial Enrich 
(Thermo Fisher Scientific), after which endothelial cells were se-
lected using Dynabeads Pan mouse IgG (Thermo Fisher Scientific) 
coated with anti-human CD146 Ab (clone SHM-57; BioLegend).
2.3 | Immunohistochemistry
Immunohistochemical staining was carried out as described pre-
viously.11 A mouse anti-human CD146 mAb (clone SHM-57; 
BioLegend), a rabbit anti-CD31 polyclonal Ab (ab28364; Abcam), 
and a mouse anti-AEBP1 mAb (ab54820; Abcam) were used.
2.4 | Reverse transcription-PCR
Single-stranded cDNA was prepared using a PrimeScript RT 
Reagent Kit with gDNA Eraser Perfect Real Time (Takara Bio). 
Reverse transcription-PCR was carried out as described previ-
ously.12 Quantitative RT-PCR (qRT-PCR) was carried out using 
TaqMan Gene Expression Assays or SYBR Select Master Mix 
(Thermo Fisher Scientific) with a 7500 Fast Real-Time PCR 
System (Thermo Fisher Scientific). GAPDH or β-actin (ACTB) was 
used as endogenous control. TaqMan assay IDs and primer se-
quences are listed in Tables S1 and S2.
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2.5 | Western blot analysis
Total cell lysate extraction and western blot analysis were under-
taken as described previously.12 A mouse anti-β-actin mAb (1:3000 
dilution, clone AC-15; Sigma-Aldrich), a rabbit anti-AEBP1 mAb 
(1:3000 dilution, ab168355; Abcam) or a mouse anti-V5 mAb (1:5000 
dilution, R960-25; Thermo Fisher Scientific) were used.
2.6 | Preparation of tumor conditioned medium
To prepare tumor conditioned medium (TCM), CRC cells were cul-
tured in a 10-cm dish in growth medium containing 10% FBS. After 
replacing this medium with serum-free medium, the cells were in-
cubated for an additional 48 h. The TCM was then collected and fil-
tered through a 0.2-μm filter.
F I G U R E  1   Detection of adipocyte enhancer-binding protein 1 (AEBP1) upregulation in tumor endothelial cells (TECs). A, Workflow to 
isolate endothelial and epithelial cells from primary colorectal cancer (CRC) and corresponding normal colorectal tissues. B, Summary of RNA 
sequencing analysis to identify genes differentially expressed between normal endothelial cells and TECs. Genes upregulated in TECs are 
indicated in red. C, Relative expression of AEBP1 in endothelial cells (EPCAM−, CD146+) isolated from normal and CRC tissues. Expression 
levels are normalized to GAPDH expression. Error bars depict SEM. **P < .01. D, Immunohistochemical staining of CD31, CD146, and AEBP1 
in representative primary CRC and adjacent normal tissues. Magnified views of the respective boxed areas are shown to the right. ANTXR1, 
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2.7 | Small interfering RNA and expression vectors
For RNA interference-induced knockdown of AEBP1, 1 × 106 cells 
were transfected with 100 pmol Silencer Select Pre-designed siRNA 
(AEBP1 siRNA1, s1145; AEBP1 siRNA2, s1146; Thermo Fisher 
Scientific) or a Silencer Select Negative Control No. 1 siRNA (Thermo 
Fisher Scientific) using a HUVEC Nucleofector Kit (Lonza). An ORF 
Expression Gateway Shuttle Clone containing full-length AEBP1 
variant 1 was obtained from GeneCopoeia. Full-length AEBP1 vari-
ant 2 cDNA was amplified by PCR using cDNA derived from HUVECs. 
Primer sequences are listed in Table S2. The AEBP1 variants were 
cloned into pLenti6/V5-DEST, and lentiviral expression vectors (Lenti-
V5-AEBP1v1 and Lenti-V5-AEBP1v2) were then constructed using a 
ViraPower Lentiviral Expression System (Thermo Fisher Scientific).
2.8 | Cell viability assays
Cells were transfected with siRNAs or infected with lentiviral vec-
tors and seeded into 96-well plates (5 × 103 cells per well). Cell vi-
ability assays were carried out using CCK-8 (Dojindo) according to 
the manufacturer’s instructions.
2.9 | Wound healing assays
Cells transfected with siRNAs were incubated for 48 hours, 
after which they were seeded into 6-well plates (2 × 105 cells per 
well). Linear wounds were drawn in the monolayer using a pi-
pette tip, and the cells were incubated for an additional 24 hours. 
Photomicrographs of the wounds and invading cells were then taken 
to evaluate wound closure. The experiments were carried out in trip-
licate under each condition.
2.10 | In vitro tube formation assay
Cells transfected with siRNAs were incubated for 48 hours, or those 
infected with lentiviral vectors were incubated for 10-14 days, after 
which they were seeded onto Matrigel (Corning) in 24-well plates 
(2.5 × 104 cells per well). After incubation for 3, 6, 12, or 24 hours, 5 ran-
domly selected fields in each well were photographed. Branch numbers 
and tube lengths were measured using ImageJ analysis software (NIH).
2.11 | Statistical analysis
Quantitative variables were analyzed using Student’s t tests or 
ANOVA with post hoc Tukey’s tests. Survival was analyzed using the 
log-rank test for 2-group comparisons. Values of P less than .05 (2-
sided) were considered statistically significant. Statistical analyses 
were carried out using JMP version 12 (SAS Institute) or GraphPad 
Prism version 5 (GraphPad Software).
2.12 | RNA sequencing, microarray, and 
xenograft studies
Methods of RNA-seq, microarray, and xenograft studies are de-
scribed in Methods S1.
3  | RESULTS
3.1 | AEBP1 is upregulated in tumor endothelial cells 
of CRC
To identify novel tumor endothelium-associated genes in CRC, we 
isolated endothelial and epithelial cells from a series of 14 CRC tissue 
samples and corresponding normal colorectal tissues (Table S3). We 
first isolated epithelial cells, using EpCAM as an epithelium marker, 
and subsequently isolated endothelial cells, using CD146 as an en-
dothelium marker (Figure 1A). This enabled us to obtain total RNA 
from endothelial cells (EpCAM−, CD146+) derived from 14 CRC tis-
sue and 12 normal tissue samples, and from epithelial cells (EpCAM+) 
derived from 14 CRC tissue and 13 normal tissue samples.
We undertook RNA-seq analysis using 3 samples each of tumor 
endothelium (patients 19, 21, and 24) and normal endothelium 
(patients 19, 20, and 22) from which we were able to collect suf-
ficient amounts of good quality RNA. RNA sequencing analysis 
confirmed enrichment of endothelial markers (PECAM1, MCAM, 
and CD34) in the EpCAM−/CD146+ cells as compared to EpCAM+ 
cells (Figure S1). This analysis revealed 18 genes significantly up-
regulated in TECs compared to NECs (Figure 1B, Table 1). The list 
TA B L E  1   Genes upregulated in tumor endothelial cells
Gene ID Gene symbol
Fold change 
(log2) P value
7472 WNT2 8.077 .037 
3381 IBSP 7.967 .027 
2328 FMO3 3.582 .047 
493869 GPX8 3.372 .027 
85360 SYDE1 3.277 .027 
100289470 LOC100289470 3.142 .042 
201191 SAMD14 3.130 .031 
6909 TBX2 3.088 .037 
100506462 SRD5A3-AS1 2.959 .031 
283298 OLFML1 2.800 .027 
79990 PLEKHH3 2.796 .044 
84168 ANTXR1 2.640 .031 
114757 CYGB 2.594 .037 
219793 TBATA 2.549 .027 
51393 TRPV2 2.544 .034 
165 AEBP1 2.496 .049 
158572 USP27X-AS1 1.867 .027
3575 IL7R 0.555 .037
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F I G U R E  2   Expression of adipocyte enhancer-binding protein 1 (AEBP1) in endothelial cells. A, Structures of genes encoding the indicated 
AEBP1 variants. Locations of the RT-PCR primers used in (B) are indicated by arrows below. B, RT-PCR of AEBP1 variants in endothelial cells 
and colorectal cancer (CRC) cell lines. C, Western blot analysis of AEBP1 in human umbilical vein endothelial cells (HUVECs). D, Quantitative 
RT-PCR of the indicated AEBP1 variants in HUVECs treated with control medium or tumor conditioned medium (TCM) derived from DLD1 
cells with or without supplemented FBS. Results are normalized to ACTB expression. Shown are means of 3 replications. E, Quantitative RT-
PCR analysis of the indicated AEBP1 variants in HUVECs treated with PBS (Ctrl), transforming growth factor (TGF)-β1 or TGF-β3. Shown are 
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of genes included a previously identified tumor endothelial marker, 
TEM8 (ANTXR1), which confirmed that our endothelial cell isola-
tion was successful. We validated the RNA-seq results by under-
taking TaqMan assays with all the samples, and most of the listed 
genes showed higher expression in TECs than in NECs or epithelial 
cells (Figures S2 and S3). Among these genes, we noted significant 
upregulation of AEBP1 in TECs (Figure 1C). Immunohistochemical 
analysis showed that AEBP1 was abundantly expressed in the vas-
cular endothelium and stroma of primary CRC tissues (Figure 1D). 
Moreover, analysis using the RNA-seq data obtained from primary 
CRC tissues in The Cancer Genome Atlas (TCGA) dataset suggested 
that higher expression of AEBP1 is associated with poorer overall 
survival (Figure S4).
Earlier studies showed that AEBP1 is expressed in adipocytes, 
fibroblasts, and vascular smooth muscle cells, but its expression 
in vascular endothelial cells has not been well documented.13-15 
Two transcriptional variants of AEBP1 have been identified in 
the human genome, and the TaqMan assay detects both vari-
ants.16 We therefore designed a RT-PCR primer pair that would 
amplify both variants but would yield different sized PCR prod-
ucts (Figure 2A). We found that endothelial cells mainly express 
AEBP1 variant 1, whereas CRC cells express variant 2 (Figure 2B). 
Moreover, endothelial cells express AEBP1 at significantly higher 
levels than do CRC cells (Figure 2B). We also designed qRT-PCR 
primer pairs to specifically detect the respective variants and ob-
served similar results (Figure S5). Western blot analysis revealed 
expression of the 2 AEBP1 variants in HUVECs (Figure 2C). Bands 
at approximately 170 kDa and 150 kDa and those at 100 kDa and 
80 kDa are considered to be variants 1 and 2, respectively. The 
larger bands (170 kDa and 100 kDa) likely represent glycosylated 
forms, as described previously.15,17 Fluorescent immunostaining 
showed AEBP1 to be present in both the nucleus and cytoplasm of 
HUVECs (Figure S6).
Notably, we found that treatment with TCM derived from CRC 
cells upregulated both AEBP1 variants in HUVECs (Figures 2D and 
S7). Induction of AEBP1 was also observed when HUVECs were 
directly cocultured with CRC cells (Figure S8). An earlier study 
showed that TGF-β induces AEBP1 expression in preadipocytes.18 
Analysis using a dataset from TCGA showed significant positive cor-
relations between expression levels of TGFB1 or TGFB3 and those 
of AEBP1 in primary CRC (Figure S9). We therefore treated HUVECs 
with TGF-β1 or TGF-β3 and confirmed that they upregulate AEBP1 
expression (Figure 2E).
3.2 | AEBP1 promotes proliferation and in vitro tube 
formation by HUVECs
To clarify the function of AEBP1 in endothelial cells, we undertook 
a series of knockdown experiments using HUVECs. We first con-
firmed successful depletion of AEBP1 mRNA and protein in HUVECs 
transiently transfected with siRNAs targeting the 2 AEBP1 variants 
(Figures 3A,B and S10). Cell viability assays showed that knock-
ing down AEBP1 suppressed HUVEC proliferation (Figure 3C); cell 
cycle analysis revealed that depleting AEBP1 induced G1 arrest 
(Figures 3D and S11). In addition, wound healing assays showed that 
AEBP1 knockdown might suppress HUVEC migration, although the 
results could be significantly affected by the reduced cell prolifera-
tion (Figure 3E). We also found that AEBP1 knockdown attenuated 
in vitro tube formation by HUVECs (Figure 3F). To assess the func-
tional difference between the 2 AEBP1 variants, we endeavored 
to design siRNAs specifically targeting the respective variants. We 
found that a siRNA targeting variant 1 had suppressive effects on 
HUVEC proliferation and in vitro tube formation similar to the siRNA 
targeting both variants (data not shown). In contrast, specific knock-
down of variant 2 was difficult due to its very low expression level in 
HUVECs and limited locations that could be used to design variant 
2-specific siRNAs.
We next constructed lentiviral expression vectors encoding 
the respective AEBP1 variants and confirmed ectopic expression 
of the mRNAs and proteins in HUVECs (Figure 4A,B). We observed 
that both protein variants were present in the nucleus and cyto-
plasm (Figure 4C), and that their ectopic expression upregulated 
proliferation and in vitro tube formation by HUVECs (Figure 4D, 
E).
3.3 | AEBP1 promotes in vivo tumor angiogenesis
We used a xenograft model to evaluate the contribution of AEBP1 to 
in vivo tumor angiogenesis. We first confirmed that cotransplanta-
tion of DLD1 cells and HUVECs into nude mice significantly enhanced 
xenograft formation as compared to transplantation of DLD1 cells 
alone (Figure S12). We then cotransplanted DLD1 cells plus HUVECs 
transfected with a siRNA targeting AEBP1 or a control siRNA into 
nude mice. We found that AEBP1 knockdown in HUVECs diminished 
microvessel formation in xenograft tumors, although it did not af-
fect tumor volumes (Figure 5A). To clarify whether AEBP1 in mouse 
F I G U R E  3   Depletion of adipocyte enhancer-binding protein 1 (AEBP1) in endothelial cells attenuates proliferation and in vitro tube 
formation. A, Quantitative RT-PCR of AEBP1 in human umbilical vein endothelial cells (HUVECs) transfected with a control siRNA (siCtrl) 
or siRNAs targeting AEBP1. Total RNA was extracted at the indicated time points after transfection, and AEBP1 expression was analyzed in 
TaqMan assays. Shown are means of 3 replications. B, Western blot analysis of AEBP1 in HUVECs transfected with the indicated siRNAs. 
Cell lysates were extracted 72 h after transfection. C, Proliferation of HUVECs transfected with the indicated siRNAs. Shown are means of 
8 replications. D, Cell cycle analysis of HUVECs transfected with the indicated siRNAs. Shown are means of 3 replications. E, Wound healing 
assays using HUVECs transfected with the indicated siRNAs. The wound was made 48 h after transfection, and photographs were taken at 
the indicated times. Representative results are shown on the left, and summarized results of 3 replications are shown on the right. F, In vitro 
tube formation by HUVECs transfected with the indicated siRNAs. Representative results are shown on the left, and summarized results of 
3 replications are shown on the right. Error bars depict SEMs. *P < .05, **P < .01
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F I G U R E  4   Ectopic expression of adipocyte enhancer-binding protein 1 (AEBP1) in endothelial cells promotes proliferation and in vitro 
tube formation. A, Quantitative RT-PCR analysis of AEBP1 variants 1 (left) and 2 (right) in human umbilical vein endothelial cells (HUVECs) 
infected with the indicated lentiviral vectors. Expression levels are normalized to ACTB expression. B, Western blot analysis of AEBP1 
in HUVECs infected with the indicated vectors. Ectopic expression of AEBP1 or LacZ was detected using an anti-V5 Ab. C, Fluorescent 
immunostaining of AEBP1 variants in HUVECs transfected with the indicated vectors. (D) Proliferation of HUVECs infected with the 
indicated vectors. (E) In vitro tube formation by HUVECs transfected with indicated vectors. Representative results are shown on the left, 


























































































































F I G U R E  5    Adipocyte enhancer-binding protein 1 (AEBP1) promotes tumor angiogenesis in CRC xenograft models. A, 
Immunohistochemical detection of CD31 in xenograft tumors derived from DLD1 cells plus human umbilical vein endothelial cells (HUVECs) 
transfected with the indicated siRNAs. Representative views are shown on the left, and summaries of microvessel densities (MVDs) are on 
the right. B, Growth of xenograft tumors treated with siRNAs targeting mouse Aebp1. Intratumoral injection of siRNAs was undertaken at 
indicated time points. Shown are means of 4 replications. C, Photographs and weights of resected tumors treated with the indicated siRNAs. 
D, Representative views of CD31 staining (left) and summaries of microvessel densities (right) in tumors treated with the indicated siRNAs. E, 
Growth of xenograft tumors derived from DLD1 cells plus HUVECs ectopically expressing LacZ or the indicated AEBP1 variants. Shown are 
means of 5 replications. F, Pictures and weights of resected tumors expressing the indicated gene. G, Representative views of CD31 staining 
(left) and summaries of microvessel densities (right) in tumors expressing the indicated gene. Error bars depict SEMs. *P < .05, **P < .01
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endothelial cells plays a role in determining the microenvironment of 
xenograft tumors, we transplanted DLD1 cells into nude mice and 
then treated the tumors with siRNAs targeting mouse Aebp1. We 
found that treatment with the siRNAs suppressed tumor growth and 
microvessel formation (Figure 5B-D). Conversely, cotransplantation 
of DLD1 cells and HUVECs ectopically expressing AEBP1 variant 2 
promoted tumor growth (Figure 5E,F). In addition, we observed that 
ectopic expression of both AEBP1 variants in HUVECs promoted mi-
crovessel formation (Figure 5G). These results suggest that upregu-
lation of AEBP1 in endothelial cells promotes tumor angiogenesis.
3.4 | AEBP1 regulates expression of angiogenesis-
related genes in endothelial cells
To clarify the mechanism by which AEBP1 regulates angiogenesis, 
we sought to identify target genes downstream of AEBP1 in en-
dothelial cells. Gene expression microarray analysis of HUVECs in 
which AEBP1 was knocked down revealed that depleting AEBP1 in 
these cells downregulated (2-fold or more) a number of genes re-
portedly associated with angiogenesis or endothelial functions, 
including AQP1 (aquaporin 1), POSTN (periostin), SELE (selectin E), 
SEMA3G (semaphorin 3G), and GJA4 (gap junction protein, alpha-
4) (Figure 6A). We validated the microarray results using qRT-PCR 
(Figure 6B). We also found that ectopic expression of AEBP1 upreg-
ulated expression of AQP1, SELE, and GJA4 in HUVECs (Figure 6C). 
These data suggest that AEBP1 might promote tumor angiogenesis 
by targeting multiple angiogenesis-related genes.
4  | DISCUSSION
In this study, we found that elevated expression of AEBP1 promotes 
tumor angiogenesis in CRC. Adipocyte enhancer-binding protein 
1 was first identified as a transcriptional repressor with carboxy-
peptidase activity in mouse preadipocytes.13 A human homologue 
of AEBP1 was found to be uniquely expressed in osteoblasts and 
adipose tissue, suggesting its involvement in determining bone mor-
phology.19 Later, an N-terminally extended isoform of AEBP1 was 
identified as aortic carboxypeptidase-like protein (ACLP), which is 
upregulated during vascular smooth muscle cell differentiation.14
Adipocyte enhancer-binding protein 1 (encoded by AEBP1 vari-
ant 2) is abundantly expressed in preadipocytes and macrophages, 
where it acts as a proinflammatory mediator and induces nuclear 
factor-κB (NF-κB) signaling.20,21 It is also expressed in the stromal 
component of mammary glands, and its overexpression in mammary 
macrophages promotes mammary epithelial hyperplasia.22 Aortic 
carboxypeptidase-like protein (encoded by AEBP1 variant 1) is char-
acterized by a signal peptide at its N-terminus and a discoidin-like 
domain.14 Aortic carboxypeptidase-like protein is a secreted protein 
that associates with the ECM. In mice, ACLP is abundantly detected 
in the ECM of collagen-rich tissues, including the vasculature, dermis, 
and connective tissue, and ACLP-null mice show abdominal wall dis-
ruption and deficient wound healing.23 Aortic carboxypeptidase-like 
protein is also highly expressed in human fibrotic lung tissue and fi-
broblasts, and it enhances myofibroblast differentiation.15,24
Adipocyte enhancer-binding protein 1 has been implicated in 
various human malignancies. For instance, AEBP1 expression is up-
regulated in glioblastoma cells, where it promotes proliferation and 
survival through regulation of various target genes involved in cell 
growth, differentiation, and apoptosis.25 Another study reported 
that AEBP1 is upregulated in melanoma cells with acquired resis-
tance to BRAF inhibition, and that AEBP1 could be a therapeutic 
target in BRAF inhibitor-resistant melanoma.26 Recently, AEBP1 was 
found to be overexpressed in gastric cancer and CRC cells, where it 
promotes proliferation, migration, invasion, and metastasis by acti-
vating NF-κB signaling.27,28 These results suggest that AEBP1 might 
exert oncogenic effects in multiple types of malignancy.
But although evidence suggests AEBP1 is expressed in stromal 
tissues, its role in cancer stroma remains unclear. In an earlier study, 
Bhati et al29 used laser capture microdissection to isolate vascular 
cells from breast tumors and normal breast tissue, and analyzed the 
respective gene expression profiles using a cDNA microarray. They 
identified a series of genes upregulated in tumor vascular cells, in-
cluding AEBP1, although its role in breast cancer angiogenesis re-
mains to be clarified. In the present study, we found that AEBP1 
is upregulated in TECs and in the stroma of primary CRC tissues. 
Notably, vascular endothelial cells expressed both AEBP1 variants, 
although variant 1 was the dominantly expressed isoform. Knocking 
down AEBP1 suppressed proliferation and in vitro tube formation 
by HUVECs. In addition, our xenograft experiments suggested 
that, when CRC cells are cotransplanted with HUVECs, depletion 
of AEBP1 in the HUVECs attenuates microvessel formation. We 
also observed that tumor growth and microvessel formation are 
suppressed when tumors are treated with siRNAs targeting mouse 
AEBP1. The experimental results obtained with HUVECs ectopically 
expressing AEBP1 are largely consistent with the knockdown exper-
iments, however, there are some discrepancies. For instance, AEBP1 
knockdown in HUVECs had no effect on xenograft tumor volumes, 
whereas ectopic expression of variant 2 in HUVECs promoted tumor 
growth. These results could be due to the limited expression level of 
endogenous variant 2 in HUVECs.
F I G U R E  6   Identification of downstream adipocyte enhancer-binding protein 1 (AEBP1) targets in endothelial cells. A, Venn diagram 
showing genes whose expression was downregulated by AEBP1 knockdown in human umbilical vein endothelial cells (HUVECs). B, 
Quantitative RT-PCR validating the microarray results for the indicated genes. Expression levels are normalized to ACTB expression. Shown 
are means of 3 replications. C, Relative expression of the indicated genes in HUVECs ectopically expressing LacZ or the indicated AEBP1 
variant. Expression levels are normalized to ACTB expression. Shown are means of 3 replications. Error bars depict SEMs. AQP, aquaporin; 
GJA4, gap junction protein, alpha-4; POSTN, periostin; SELE, selectin E; SEMA3G, semaphorin 3G; siCtrl, control siRNA
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We also found that AEBP1 might exert its function by altering 
expression of downstream target genes. Aquaporin 1 is a water 
channel protein widely expressed in epithelial and endothe-
lial cells, and is involved in water transport and cell migration.30 
Expression of AQP1 is elevated in various tumor types and is asso-
ciated with cell migration, angiogenesis, and metastasis.31 In CRC 
tissues, AQP1 expression is elevated early during tumorigenesis 
and is maintained through the late stages of cancer progression.32 
Aquaporin 1 is highly expressed in proliferating tumor microves-
sels,33 and a cancer model in AQP1-null mice showed impaired 
tumor angiogenesis.34 A recent study also showed that pharma-
cological blockade of AQP1 suppressed in vitro tube formation by 
HUVECs.35
Also known as osteoblast-specific factor 2, POSTN is a se-
creted ECM protein originally identified in osteoblasts.36 Periostin 
belongs to the superfamily of TGF-β-inducible proteins and pro-
motes integrin-dependent cell adhesion and motility. It is normally 
expressed in collagen-rich fibrous connective tissues, including 
periosteum, as well as in fibroblasts of normal tissues. By acti-
vating integrin-mediated signaling pathways, POSTN promotes 
cell survival, angiogenesis, and resistance to hypoxia-induced cell 
death, and its expression is elevated in esophageal, gastric, col-
orectal, and pancreatic cancers.36 In CRC, POSTN is expressed 
by stromal cells, and elevation of its expression is associated with 
metastasis and a poor prognosis.37-40 Periostin also reportedly 
promotes tumor angiogenesis. In breast cancer, POSTN mediates 
angiogenesis by upregulating VEGF receptor (FLK1/KDR) through 
an integrin αvβ3-FAK-mediated signaling pathway.41 In addition, 
POSTN promotes proliferation, migration, and in vitro tube forma-
tion by HUVECs, and that it promotes tumor angiogenesis through 
Erk/VEGF signaling in pancreatic cancer.42
E-selectin is a major adhesion receptor on endothelial cells, 
and its expression is induced by inflammatory cytokines, includ-
ing interleukin-1β and tumor necrosis factor-α.43 Multiple lines 
of evidence suggest that E-selectin-mediated adhesion of CRC 
cells to endothelial cells is an important determinant of metas-
tasis. E-selectin is expressed on activated endothelial cells and 
is upregulated during metastatic colonization of the liver.44 
Anti-E-selectin Abs or antisense oligonucleotides that suppress 
E-selectin expression have been shown to attenuate experimen-
tal liver metastasis.45 These reports suggest that AEBP1 might 
promote CRC metastasis by inducing E-selectin expression in en-
dothelial cells, although further study will be needed to evaluate 
this possibility.
As a class 3 semaphorin, SEMA3G is primarily expressed by en-
dothelial cells that acts to control endothelial and smooth muscle 
function.46 Recently, SEMA3G was shown to promote peroxisome 
proliferator-activated receptor-γ-driven migration of HUVECs.47 
GJA4, also known as connexin 37 (Cx37), is a transmembrane pro-
tein that forms gap junctions and mediates cell-cell communication. 
Among the 21 connexin isoforms, HUVECs express Cx37, Cx40, and 
Cx43, and knocking down that expression suppresses angiogenic 
activity.48
There are several limitations in our study. Although we found 
that AEBP1 could induce angiogenesis-related genes in endothelial 
cells, it remains unclear whether AEBP1 acts directly within the nu-
cleus to regulate transcription of target genes. To clarify the mo-
lecular mechanism by which AEBP1 promotes tumor angiogenesis, 
identification of factors that associate with AEBP1 in endothelial 
cells will be necessary. Second, it remains unclear whether or not 
the 2 AEBP1 variants play similar roles in endothelial cells. We found 
that ectopic expression of variant 2 exerted similar or even stronger 
effects than variant 1 in HUVECs, but our results should be carefully 
interpreted, given the low expression levels of endogenous variant 
2. In addition, the effect of glycosylation on AEBP1 function remains 
to be clarified. Finally, we found that AEBP1 is abundantly expressed 
in the stroma of CRC tissues, but its role in cell types other than 
endothelial cells remains to be determined. Further study will be 
needed to clarify the function of AEBP1 in cancer stromal cells, in-
cluding cancer-associated fibroblasts.
In summary, we found that expression of AEBP1 is frequently 
elevated in TECs within CRC tissues, and that upregulation of AEBP1 
might contribute to tumor angiogenesis. Endothelial expression of 
AEBP1 is induced by CRC cells, and AEBP1 could promote angiogen-
esis by inducing angiogenesis-related genes, including AQP1. These 
results suggest that AEBP1 signaling could be a useful therapeutic 
target in CRC.
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